TransCon PTH Ascendis Pharma US
TransCon is an investigational long acting prodrug of parathyroid hormone PTH in development as a once daily hormone replacement therapy It is designed to restore physiologic levels of PTH 24 hours a day By doing so we believe TransCon PTH can address both the short term symptoms and long term complications of hypoparathyroidism